NCCN Guidelines for Breast Cancer Staging

Introduction to Staging Guidelines

The NCCN guidelines for breast cancer staging utilize the AJCC TNM anatomic staging system, supplemented by prognostic biological markers including ER/PR status, HER2 status, and tumor grade to guide treatment decisions and estimate prognosis 1, 2, 3

For patients with clinical stage 0, I, or II disease, the baseline staging workup should include history and physical examination, bilateral diagnostic mammography, breast ultrasound as clinically indicated, pathology review, determination of ER and PR status, HER2 status determination, complete blood count, platelet count, and liver function tests, and genetic counseling if high-risk for hereditary breast cancer 1, 2, 4
The American College of Surgeons and the NCCN recommend that patients with stage I or II disease should not undergo additional staging studies such as bone scan, CT, or other abdominal imaging unless they have signs or symptoms suggestive of metastatic disease 5, 4

Breast MRI is optional for staging and should be performed using a dedicated breast coil by a team capable of MRI-guided biopsy, with considerations for women with very dense breast tissue, positive axillary nodes and occult primary tumor, evaluation of chest wall involvement, and assessment of extent of disease in Paget's disease 5, 4, 7
The NCCN guidelines note that MRI has a high false-positive rate, its use has not been shown to increase likelihood of negative margins or decrease conversion to mastectomy, and no randomized prospective data demonstrate improved long-term outcomes with MRI staging 5, 4, 1

The NCCN staging approach integrates both anatomic and biological factors, including ER/PR status, HER2 status, and tumor grade, which are essential for determining benefit of endocrine therapy, targeted therapy decisions, and prognostic staging 1, 2, 3, 5

Comedo necrosis is an important prognostic factor that should be documented in pathology reports, as it is an independent predictor of ipsilateral breast tumor recurrence, and complete pathologic assessment must document its presence 8
When Paget's disease is diagnosed, MRI should be considered to assess extent of disease and identify additional disease, and the workup includes bilateral diagnostic mammography with ultrasound as necessary, followed by full-thickness skin biopsy of the involved nipple-areolar complex 7, 9
Patients with clinical T3N1M0 disease require additional staging studies including bone scan, abdominal imaging, and chest imaging, as they are at higher risk for occult metastatic disease 6, 4